1,7-dihydroxy-4-methoxyxanthone, also known as **mangiferin**, is a natural polyphenol compound found in various plants, particularly in the mango tree (Mangifera indica). It's a bioactive molecule with a range of potential health benefits that have attracted significant research interest.
Here's why 1,7-dihydroxy-4-methoxyxanthone (mangiferin) is important for research:
**Pharmacological Properties and Potential Applications:**
* **Antioxidant activity:** Mangiferin has demonstrated strong antioxidant properties, helping to protect cells from damage caused by free radicals. This makes it potentially useful for preventing or treating conditions related to oxidative stress, such as cancer, neurodegenerative diseases, and cardiovascular disease.
* **Anti-inflammatory activity:** Research suggests that mangiferin can suppress inflammation by inhibiting the production of pro-inflammatory cytokines. This property could be beneficial for managing inflammatory conditions like rheumatoid arthritis and inflammatory bowel disease.
* **Anti-diabetic activity:** Studies have shown that mangiferin can improve glucose tolerance and insulin sensitivity, potentially making it a helpful agent for managing type 2 diabetes.
* **Anti-cancer activity:** Mangiferin has exhibited anti-proliferative and apoptotic effects in various cancer cell lines. It may be able to inhibit cancer cell growth and induce their death, making it a promising candidate for cancer prevention and treatment.
* **Neuroprotective activity:** Mangiferin has shown neuroprotective effects in animal models, potentially protecting against neuronal damage caused by oxidative stress and neuroinflammation. This could be relevant for managing neurodegenerative diseases like Alzheimer's and Parkinson's.
* **Hepatoprotective activity:** Research suggests that mangiferin can protect the liver from damage caused by toxins and other harmful agents, potentially benefiting individuals with liver disease.
* **Antimicrobial activity:** Mangiferin has demonstrated antimicrobial activity against a range of bacteria and fungi, suggesting its potential use in developing new antibiotics.
**Research Focus:**
* **Understanding mechanisms of action:** Researchers are actively investigating the mechanisms by which mangiferin exerts its various pharmacological effects to gain a better understanding of its therapeutic potential.
* **Clinical trials:** Ongoing clinical trials are evaluating the safety and efficacy of mangiferin in treating various diseases, including cancer, diabetes, and inflammatory conditions.
* **Drug development:** Efforts are underway to develop mangiferin-based drugs or formulations for therapeutic applications.
**Overall, 1,7-dihydroxy-4-methoxyxanthone (mangiferin) is a promising natural compound with a wide range of pharmacological properties. Ongoing research is exploring its potential therapeutic applications for various diseases and conditions, making it a significant area of interest in the field of medicinal chemistry and pharmacology.**
**Important Note:** While mangiferin shows great promise in research, it's crucial to consult with a healthcare professional before using it for medicinal purposes. It is important to understand its safety profile and potential interactions with other medications.
1,7-dihydroxy-4-methoxyxanthone : A member of the class of xanthones that is 9H-xanthene substituted by hydroxy groups at positions 1 and 7, a methoxy group at position 4 and an oxo group at position 9. It has been isolated from the stems of Cratoxylum cochinchinense. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Flora | Rank | Flora Definition | Family | Family Definition |
---|---|---|---|---|
Cratoxylum | genus | [no description available] | Hypericaceae | [no description available] |
ID Source | ID |
---|---|
PubMed CID | 5465785 |
CHEMBL ID | 484030 |
CHEBI ID | 67553 |
Synonym |
---|
1,7-dihydroxy-4-methoxy-9h-xanthen-9-one |
1,7-dihydroxy-4-methoxy-xanthen-9-one |
nsc-661737 |
nsc661737 |
1,7-dihydroxy-4-methoxyxanthone |
1,7-dihydroxy-4-methoxyxanthen-9-one |
CHEMBL484030 , |
chebi:67553 , |
1,7-dihydroxy-4-methoxy-9h-xanthenone |
87339-76-2 |
9h-xanthen-9-one, 1,7-dihydroxy-4-methoxy- |
DTXSID80236284 |
bdbm50485132 |
Q27136019 |
STARBLD0026872 |
AKOS040760874 |
Role | Description |
---|---|
metabolite | Any intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites. |
plant metabolite | Any eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms. |
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Class | Description |
---|---|
aromatic ether | Any ether in which the oxygen is attached to at least one aryl substituent. |
phenols | Organic aromatic compounds having one or more hydroxy groups attached to a benzene or other arene ring. |
xanthones | Any member of the class of xanthenes based on a xanthone skeleton. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID661918 | Antiviral activity against Influenza A virus PR/8/34 H1N1 infected in dog MDCK cells assessed as reduction in virus-induced cytopathic effect at 5 ug/mL | 2012 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 22, Issue:11 | Xanthones from Polygala karensium inhibit neuraminidases from influenza A viruses. |
AID661913 | Inhibition of Influenza A virus H1N1 neuraminidase using 4-MU-NANA as substrate by fluorescence assay | 2012 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 22, Issue:11 | Xanthones from Polygala karensium inhibit neuraminidases from influenza A viruses. |
AID775269 | Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production at 50 uM after 24 hrs by Griess assay relative to control | 2013 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 23, Issue:21 | Inhibitory constituents from the aerial parts of Polygala tenuifolia on LPS-induced NO production in BV2 microglia cells. |
AID1434698 | Cytotoxicity against Taxol-resistant human SMMC7721 cells measured after 48 hrs by MTT assay | 2017 | Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3 | Structure-activity relationships of diverse xanthones against multidrug resistant human tumor cells. |
AID333524 | Cytotoxicity against human MCF7 cells after 3 days by SRB assay | 2004 | Journal of natural products, Nov, Volume: 67, Issue:11 | Prenylated benzophenones and xanthones from Hypericum scabrum. |
AID775267 | Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess assay | 2013 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 23, Issue:21 | Inhibitory constituents from the aerial parts of Polygala tenuifolia on LPS-induced NO production in BV2 microglia cells. |
AID492176 | Inhibition of RXRalpha transcriptional activity in african green monkey CV1 cells co-expressing with TREpal-tkCAT at 10 uM by reporter gene assay | 2010 | Journal of natural products, Jul-23, Volume: 73, Issue:7 | Bioactive xanthones from the stems of Cratoxylum formosum ssp. pruniflorum. |
AID661915 | Inhibition of wild type H1N1 swine influenza virus neuraminidase using 4-MU-NANA as substrate by fluorescence assay | 2012 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 22, Issue:11 | Xanthones from Polygala karensium inhibit neuraminidases from influenza A viruses. |
AID333523 | Cytotoxicity against human A549 cells after 3 days by SRB assay | 2004 | Journal of natural products, Nov, Volume: 67, Issue:11 | Prenylated benzophenones and xanthones from Hypericum scabrum. |
AID661916 | Inhibition of oseltamivir-resistant H1N1 swine influenza virus neuraminidase H274Y mutant using 4-MU-NANA as substrate by fluorescence assay | 2012 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 22, Issue:11 | Xanthones from Polygala karensium inhibit neuraminidases from influenza A viruses. |
AID1434699 | Cytotoxicity against Taxol-resistant human A549 cells measured after 48 hrs by MTT assay | 2017 | Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3 | Structure-activity relationships of diverse xanthones against multidrug resistant human tumor cells. |
AID1434700 | Cytotoxicity against human MCF7/ADR cells measured after 48 hrs by MTT assay | 2017 | Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3 | Structure-activity relationships of diverse xanthones against multidrug resistant human tumor cells. |
AID661912 | Selectivity ratio of IC50 for wild type H1N1 swine influenza virus neuraminidase to IC50 for oseltamivir-resistant H1N1 swine influenza virus neuraminidase H274Y mutant | 2012 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 22, Issue:11 | Xanthones from Polygala karensium inhibit neuraminidases from influenza A viruses. |
AID661914 | Inhibition of Influenza A virus H9N2 neuraminidase using 4-MU-NANA as substrate by fluorescence assay | 2012 | Bioorganic & medicinal chemistry letters, Jun-01, Volume: 22, Issue:11 | Xanthones from Polygala karensium inhibit neuraminidases from influenza A viruses. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 4 (80.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.84) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |